Latest News and Press Releases

HAMILTON, Bermuda, April 17, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...

HAMILTON, Bermuda, April 08, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...

- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period- Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3 trial of rilonacept in...

– Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial – Enrollment and dosing of patients commenced in mavrilimumab global Phase 2 trial – KPL-716 advancing into two...

HAMILTON, Bermuda, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Cowen and Company 39th Annual Healthcare Conference on...

HAMILTON, Bermuda, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Barclays Global Healthcare Conference on Tuesday, March...

HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various...

HAMILTON, Bermuda, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday,...

- Phase 2 enrollment completed; interim clinical data show reductions in both inflammation and reported pain after first dose and throughout treatment period - Pivotal Phase 3 clinical trial,...

– Rilonacept pivotal Phase 3 clinical trial initiating this year– Mavrilimumab pre-IND meeting complete; plans for global Phase 2 clinical trial advancing– KPL-716 advancing into multiple chronic...